Current and Novel Approach for Influenza vaccines

The first and foremost efforts to develop influenza vaccines were initiated soon after influenza A and B viruses were identified as the etiologic agents of clinical influenza. The United States in 1945 has approved the first commercial vaccines using whole-inactivated influenza virus for use. The flu vaccine is an annual vaccination using a vaccine to protect against the highly variable influenza virus that is specific for a given year. Risk management and effectiveness of vaccines are important for public health.

  • Genetic and evolution of virus and host
  • Risk management and effectiveness of vaccines
  • Targeting strategies for influenza vaccines
  • Clinical trials of influenza based vaccines

Related Conference of Current and Novel Approach for Influenza vaccines

August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

Singapore
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria
November 05-06, 2020

9th Asia Pacific STD and Infectious Diseases Congress

Tokyo, Japan
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
February 22-23, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore

Current and Novel Approach for Influenza vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in